Gouveia H, Urquiza-Martinez M, Manhaes-de-Castro R, Costa-de-Santana B, Villarreal J, Mercado-Camargo R
Int J Mol Sci. 2022; 23(15).
PMID: 35955475
PMC: 9369232.
DOI: 10.3390/ijms23158344.
Goedeke L, Wagschal A, Fernandez-Hernando C, Naar A
Biochim Biophys Acta. 2016; 1861(12 Pt B):2047-2052.
PMID: 26968099
PMC: 5375104.
DOI: 10.1016/j.bbalip.2016.03.007.
Fond A, Lee C, Schulman I, Kiss R, Ravichandran K
J Clin Invest. 2015; 125(7):2748-58.
PMID: 26075824
PMC: 4563683.
DOI: 10.1172/JCI80300.
Larach D, Cuchel M, Rader D
Clin Lipidol. 2014; 8(6):635-648.
PMID: 25374625
PMC: 4217288.
DOI: 10.2217/clp.13.73.
Remaley A, Norata G, Catapano A
Cardiovasc Res. 2014; 103(3):423-8.
PMID: 24951539
PMC: 4133558.
DOI: 10.1093/cvr/cvu141.
Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein.
Thompson C, Ali A, Quraishi N, Lu Z, Hammond M, Sinclair P
ACS Med Chem Lett. 2014; 2(6):424-7.
PMID: 24900324
PMC: 4018150.
DOI: 10.1021/ml100309n.
HDL: to treat or not to treat?.
Pirillo A, Tibolla G, Norata G, Catapano A
Curr Atheroscler Rep. 2014; 16(8):429.
PMID: 24890632
DOI: 10.1007/s11883-014-0429-x.
eNOS activation by HDL is impaired in genetic CETP deficiency.
Gomaraschi M, Ossoli A, Pozzi S, Nilsson P, Cefalu A, Averna M
PLoS One. 2014; 9(5):e95925.
PMID: 24830642
PMC: 4022511.
DOI: 10.1371/journal.pone.0095925.
Established and emerging approaches for the management of dyslipidaemia.
Norata G
Scientifica (Cairo). 2013; 2012:482423.
PMID: 24278703
PMC: 3820450.
DOI: 10.6064/2012/482423.
Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations.
Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, Ribeiro S, Rocha-Pereira P, Cotterill E
Dis Markers. 2013; 35(2):85-96.
PMID: 24167352
PMC: 3774979.
DOI: 10.1155/2013/724706.
Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study.
Genoux A, Ruidavets J, Ferrieres J, Combes G, Lichtenstein L, Pons V
J Lipid Res. 2013; 54(9):2550-8.
PMID: 23794714
PMC: 3735951.
DOI: 10.1194/jlr.P036335.
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour A, Akhlaghi F
Clin Pharmacokinet. 2013; 52(8):615-26.
PMID: 23658137
PMC: 3720705.
DOI: 10.1007/s40262-013-0071-8.
Statin treatment improves plasma lipid levels but not HDL subclass distribution in patients undergoing percutaneous coronary intervention.
Tian L, Chen Y, Li C, Zeng Z, Xu Y, Long S
Lipids. 2013; 48(2):127-37.
PMID: 23275076
DOI: 10.1007/s11745-012-3750-6.
The 50th anniversary of the Kefauver-Harris Amendments: efficacy assessment and the randomized clinical trial.
Rick Turner J
J Clin Hypertens (Greenwich). 2012; 14(11):810-5.
PMID: 23126358
PMC: 8108842.
DOI: 10.1111/jch.12012.
Targeting high density lipoproteins in the prevention of cardiovascular disease?.
Larach D, deGoma E, Rader D
Curr Cardiol Rep. 2012; 14(6):684-91.
PMID: 22991041
PMC: 3517174.
DOI: 10.1007/s11886-012-0317-3.
Relationship between atorvastatin dose and the harm caused by torcetrapib.
Barter P, Rye K, Beltangady M, Ports W, Duggan W, Boekholdt S
J Lipid Res. 2012; 53(11):2436-42.
PMID: 22941786
PMC: 3466012.
DOI: 10.1194/jlr.P026328.
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag. 2012; 8:323-31.
PMID: 22661899
PMC: 3363149.
DOI: 10.2147/VHRM.S25238.
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Fayad Z, Mani V, Woodward M, Kallend D, Abt M, Burgess T
Lancet. 2011; 378(9802):1547-59.
PMID: 21908036
PMC: 4151875.
DOI: 10.1016/S0140-6736(11)61383-4.
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.
Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih D
J Clin Invest. 2011; 121(7):2693-708.
PMID: 21701070
PMC: 3223817.
DOI: 10.1172/JCI42946.
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.
Rayner K, Sheedy F, Esau C, Hussain F, Temel R, Parathath S
J Clin Invest. 2011; 121(7):2921-31.
PMID: 21646721
PMC: 3223840.
DOI: 10.1172/JCI57275.
